TIGIT and acute myeloid leukemia: Anti-TIGIT monotherapy has shown encouraging results in the treatment of diverse cancers, and combining TIGIT blockade with the inhibition of adenosine production, restores NK cell-mediated AML cell killing, which might enhance treatment efficacy (246).